Abstract
Antiplatelet therapy is essential for patients with acute coronary syndrome (ACS). Aspirin (acetylsalicylic acid, or ASA) is one of the most commonly used medications for this purpose, particularly in the context of dual antiplatelet therapy (DAPT). However, hypersensitivity to aspirin can pose significant challenges, especially when this treatment is indispensable. This report discusses the case of a patient with non-ST-segment elevation myocardial infarction (NSTEMI) who presented with an allergic reaction to aspirin. An aspirin desensitization protocol was successfully implemented, allowing for the initiation of DAPT following dual angioplasty. This case highlights the importance and feasibility of aspirin desensitization in ensuring optimal management of patients with aspirin allergy, in a cardiac emergency setting.